Trial of S-1 Plus Cisplatin in Gastric Cancer

NCT01198392 ↗

Phase 3 Unknown 270 enrolled Sun Yat-sen University

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.

Timeline

Start: 2008-09
Primary completion: 2011-12
Completion: 2011-12

Publications

Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Cisplatin	Other / unclassified	20 mg/m2	Intravenous
Subject	S-1	Small molecule	80 mg/m2	Oral
Comparator	fluorouracil	Small molecule	800 mg/m2	Intravenous

Trial of S-1 Plus Cisplatin in Gastric Cancer

Summary

Timeline

Publications

Drugs

Indications